H1N1 Tamiflu and Relenza Resistance in Kansas Case NOT



	Home	Founder	What's New	In The News	Consulting



H1N1 Consulting Paradigm Shift Viral Evolution Intervention Monitoring Vaccine Screening Vaccine Development Expression Profiling Drug Discovery Custom Therapies Patents	Audio:May20 Jun17 Jul15 Aug19 twitter Live feed of underlying pandemic map data here Commentary H1N1 Tamiflu and Relenza Resistance in Kansas Case NOT Recombinomics Commentary 23:40 August 25, 2010 On August 26 the CDC notified Recombinomics that the GISAID entry on antiviral resistance is in ERROR. A/Kansas/05/2010 is SENSITIVE to oseltamivir and Zanamivir. The US CDC released an NA sequence, A/Kansas/05/2010, today (at GISAID), which had in vivo Tamiflu (oseltamivir) and Relenza (zanamivir) resistance. The sample was collected March 17, 2010 and had two non-synonymous changes, S363N and I 466M (S364N and I467M in N1 numbering). A second sequence, A/Connecticut/23/2009, was also released by the CDC today, and it also had I466M, which was also on an earlier sequence from Poland, A/Poland/37/2009. None of the above sequences had H274Y. Resistance to the two first line neuramindase inhibitors (and it is likely that the M2 sequence also has S31N, conferring resistance to adamantines) in the same sequence is cause for concern. Information on the resistance in the patients from Connecticut and Poland would be useful. Media Links Recombinomics Presentations Recombinomics Publications Recombinomics Paper at Nature Precedings